A recent study showed that (a) miR-361-3p, a tumor suppressor whose expression is decreased in multiple cancer types including PC, normally binds to the 3′UTRs of AR-V7 (which differs from the 3′ UTR of AR-FL), and the MAP kinase-interacting serine/threonine kinase 2 (MKNK2) transcript, leading to suppression of AR-V7 and MKNK2 protein expression and enzalutamide sensitivity in vitro and in vivo and (b) enzalutamide decreases the expression of miR-361-3p by upregulating hypoxic signaling [110]. The gene discussed is MKNK2; the disease is pachyonychia congenita.